Torrent Pharmaceuticals Ltd.’s consolidated net profit surged 11% in the fourth quarter of financial year 2025, according to an exchange filing on Tuesday.
The pharma company’s bottom line stood at Rs 498 crore during January- March period in comparison to Rs 449 crore in the year-ago period.
Torrent Pharma Q4 Highlights (Consolidated, YoY)
- Revenue at Rs. 2,959 crores; grew by 8% YoY.
- Gross Margin: 75.3%, Op. EBITDA margin at 32.6%.
- Op. EBITDA at Rs.964* crores, up by 9% YoY.
- Net Profit after tax at Rs. 498 crores, up by 11% YoY.
*Adjusted for one time impact on gross margin of Rs. 17 crores, Op. EBITDA stands at Rs. 981 crores, up 11% with Op EBITDA margin at 33.1%. Impact is on account of revaluation of inventory at cost or NRV whichever is lower of an in-licensed product which went off patent.
Performance summary:
| Results | Q4 FY25 | Q4 FY24 | YoY
% |
FY25 | FY24 | YoY
% |
||||
| Rs cr | % | Rs cr | % | Rs cr | % | Rs cr | % | |||
| Revenues | 2,959 | 2,745 | 8% | 11,516 | 10,728 | 7% | ||||
| Gross profit | 2,228 75.3% | 2,066 75.3% | 8% | 8,740 75.9% | 8,042 75.0% | 9% | ||||
| Op EBITDA* | 964 | 32.6% | 883 32.2% | 9% | 3,721 32.3% | 3,368 31.4% | 10% | |||
| Exceptional item** | (24) | -0.8% | 0.0% | – | (24) | -0.2% | 88 | 0.8% | – | |
| PAT^ | 498 | 16.8% | 449 16.4% | 11% | 1,911 16.6% | 1,656 15.4% | 15% | |||
| R&D spend | 150 | 5.1% | 139 | 5.1% | 8% | 581 | 5.0% | 527 | 4.9% | 10% |
Appointment of Managing Director:
We are pleased to share that as part of our long-term strategic vision and succession planning, the Board has approved the appointment of Aman Mehta as Managing Director, effective 1st August 2025. This appointment is aligned with our commitment to building a strong, future-ready leadership team capable of delivering sustainable value to all stakeholders.
The Company has distributed an interim dividend of Rs. 26/- per equity share of face value of Rs. 5/- during the year. Further, the Board (subject to Shareholder’s approval) has recommended a final dividend of Rs. 6/- per share.
India:
- India revenues at Rs 1,545 crores were up by 12% led by outperformance in focus therapies. • As per AIOCD secondary market data, IPM growth for the quarter was 8%.
- Torrent’s chronic business grew at 14% vs IPM growth of 9%
- On a MAT basis Torrent has outperformed the market across focused therapies aided by strong new launch performance. Torrent has 21 brands in the Top 500 brands in IPM, with 14 brands having more than Rs.100 crores sales.
- For FY25, revenues were Rs 6,393 crores, up by 13%.
Brazil:
- Brazil revenues at Rs 351 crores, were down by 6%, impacted by steep Brazilian Real (BRL) depreciation.
- Constant currency revenues at R$ 234 million, were up by 5%. Lower than expected annual price annual price increase on April 1st resulted in the wholesalers reducing their inventory than usual. • As per IQVIA , Torrent grew at 13% vs market growth of 7%.
- Torrent has sixty three products under ANVISA review.
- For FY25, revenues were Rs 1,100 crores, down by 2% (Constant currency revenue: R$ 734 million, up by 9%).
Germany:
- Germany revenues at Rs 286 crores, were up by 2%.
- Constant currency revenues at EUR 31 million, were up by 1%.
- New tender wins continue to grow backed by cost improvement initiatives.
- For FY25, revenues were Rs 1,139 crores, up by 6% (Constant currency revenue: Euro 126 million, up by 5%).
United States:
- US business revenues at Rs 302 crores, were up by 15%.
- Constant currency revenues at $35 million, were up by 10% compared to same period in the previous year.
- For FY25, revenues were Rs 1,100 crores, up by 2% (Constant currency revenue: $130 million). Adjusted for one off income in FY 24, constant currency growth at 1%.